Compare
Equillium, Inc. vs Nuvectis Pharma, Inc. vs Tvardi Therapeutics, Inc. vs Valion Bio, Inc.
| Latest fiscal year | Equillium, Inc. EQ | Nuvectis Pharma, Inc. NVCT | Tvardi Therapeutics, Inc. TVRD | Valion Bio, Inc. VBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$22.40M | -$26.44M | -$18.21M | -$8.88M |
| EPS (Diluted) | -$0.39 | -$1.32 | -$3.26 | n/a |
| Operating cash flow | -$22.75M | -$16.01M | -$23.50M | -$7.00M |
| Free cash flow | -$22.79M | n/a | n/a | -$7.04M |
| Cash & equivalents | $30.28M | $31.63M | $20.73M | $12.64M |
| Total assets | $31.89M | $31.71M | $32.07M | $31.61M |
| Total liabilities | $3.29M | $13.30M | $11.13M | $7.44M |
| Shareholders' equity | $28.60M | $18.41M | $20.95M | $16.80M |
| Return on year-end equity | -78.3% | -143.6% | -87.0% | -52.9% |
| Shares outstanding | 61.46M | 25.68M | 9.38M | 2.53M |
Revenue, most recent five fiscal years
| Fiscal year | Equillium, Inc. | Nuvectis Pharma, Inc. | Tvardi Therapeutics, Inc. | Valion Bio, Inc. |
|---|---|---|---|---|
| Latest | $41.09M Ended 2024-12-31 | n/a | $7.14M Ended 2024-12-31 | $780.0K Ended 2024-12-31 |
| 1 year earlier | $36.08M Ended 2023-12-31 | n/a | $20.97M Ended 2023-12-31 | $1.18M Ended 2023-12-31 |
| 2 years earlier | $15.76M Ended 2022-12-31 | n/a | $41.87M Ended 2022-12-31 | $1.84M Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $23.03M Ended 2021-12-31 | $1.26M Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $135.08M Ended 2020-12-31 | n/a |